SUPPLEMENT

Q2 2026 — Investor materials

Q2 2026PDF · 6 pages417 KB
June 11, 2026
2026 Q2 Economic Factors and J&J Announcements
Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well
as public commentary made by management during the quarter and recent earnings calls. Any additional information
included herein is provided as phasing considerations and should not be construed as guidance.
Phasing considerations:
As a reminder, please note the following:
• 	The impact of the Intra-Cellular benefit laps in Q2.
• 	In 2026, we benefit from a 53 rd week in our financial calendar, which is worth approximately 100 basis points
to full year sales growth and neutral to bottom line due to expenses for an additional week.
• 	We expect heavier investment in the first half of the year.
• 	For your convenience, as we progress through 2026, we have attached QTD and FY segment P&Ls for 2025.
Macro-economic factors:
• 	Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as
well as interest income on our cash position.
• 	Tariffs: In Q4 we noted a 2026 approximate impact of $500MM, exclusively related to our MedTech business,
based on tariff information known at the time. We are reviewing the impact of the Supreme Court’s decision
to deny the IEEPA tariff authority, the outcomes of recent hearings, and the implementation of new tariffs
through Section 122 at a flat 10%. We will provide further guidance as we have additional clarity on the
financial impact of these decisions and will continue to monitor tariffs and their potential impact to our
business.
• 	Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to
experience, impacts to the Company's business resulting from the Russia-Ukraine war, conflict in the Middle
East as well as increasing tensions between the U.S. and China.
• 	Foreign Exchange: We do not offer guidance or predictions on currency movements, but as highlighted by Joe
during the Q1 2026 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar of 1.17. The Euro

-- 1 of 6 --

Spot Rate averaged 1.17 in April, 1.17 in May, compared to a current spot rate of approximately 1.15 over the
past few days. As a reminder, our results are based on a basket of currencies, of which, not all align to the
Euro.
Conference participation
J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for
the events below have been attached for your convenience.
• 	Bank of America 2026 Healthcare Conference: John Reed – Executive Vice President - Pharmaceuticals,
R&D fireside chat with Jason Gerberry - Bofa Merrill Lynch Asset Holdings Inc - Analyst
• 	2026 RBC Capital Markets Global Healthcare Conference: Michael Bodner – Company Group Chair,
Electrophysiology & Neurovascular, fireside chat with Shagun Singh - RBC Capital Markets Inc - Analyst
• 	Bernstein’s 42nd Annual Strategic Decisions Conference: Joaquin Duato – Chairman of the Board, Chief
Executive Officer, fireside chat with Lee Hambright – Sanford C Bernstein & Co LLC – Analyst
• 	Goldman Sachs 47th Annual Global Healthcare Conference: Tom Cavanaugh– Group Chairman Innovative
Medicine, North America, fireside chat with Asad Haider – Goldman Sachs - Managing Director

-- 2 of 6 --

Announcements
Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom,
and MedTech News & Events page.
• 	M&A: Firefly Bio, Inc. Acquisition; Atraverse Medical, Inc. Acquisition
• 	Talc: please visit factsabouttalc.com for the latest company statements
• 	Enterprise: Generation Fine Campaign; Ryan Koors- VP of J&J IR Announcement
• 	Innovative Medicine:
o 	CAPLYTA: APA and ASCP long-term data in MDD; First network meta-analysis results;
Supplemental New Drug Application FDA Approval
o 	ERLEADA: Phase 3 PROTEUS study
o 	ICOTYDE: Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies
o 	IMAAVY: FDA grants Priority Review wAIHA; Phase 3 Vivacity-MG3 study; Phase 2/3 study (wAIHA)
o 	INLEXZO: Standard-of-care bladder cancer survey; Permanent Billing Code
o 	JNJ-4804: Phase 2b data results
o 	Nipocalimab: SLE Phase 2 results; Phase 2 DAHLIAS Sjögren's disease results;
o 	RYBREVANT + LAZCLUZE: Phase 1/1b CHRYSALIS-2 study NSCLC
o 	RYBREVANT FASPRO: Phase 1b/2 OrigAMI-4 study
o 	TECVAYLI: Phase 3 MajesTEC-9 study
o 	TREMFYA: FDA label expansion approval sBLA; Phase 3 FUZION study
• 	MedTech:
o 	Shockwave: Shockwave™ C2 Aero Coronary IVL Catheter Launch
o 	OTTAVA: Clinical Study Results for a New Soft-Tissue Surgical Robotic System
o 	EP: CARTOSOUND SONATA Module launch HRS 2026; Launch of VARIPULSE Pro in Europe
following CE Mark approval
o 	Vision: ASCRS 2026 New Clinical Data for TECNIS PureSee IOL; Expanded U.S. Availability of
TECNIS PureSee IOL
o 	Orthopaedics: Miniature Radiofrequency Tracking Technology Acquisition; CGBIO distribution
agreement

-- 3 of 6 --

J&J earnings calls:
• 	Q1 2026 earnings call: Full year 2026 Operational Sales Guidance of $99.7B - $100.7B or 5.9% - 6.9% and
Adjusted Operational Earnings Per Share of $11.30 - $11.50 or 4.7% - 6.7% was provided on our
Q1 2026 Earnings Call. For your convenience, the final Q1 2026 earnings transcript and presentation are
attached. Full Q1 2026 earnings call operational commentary and key drivers can be listened to here and the
Q1 2026 10-Q can be found here.
• 	Q2 2025 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth
rates for Q2 2025. Full Q2 2025 operational commentary, key drivers, and one-timers can be listened
to here and the Q2 2025 10-Q can be found here. For your convenience, the final Q2 2025 earnings
transcript and presentation are attached.
Q2 2025:
o 	Enterprise: $23.7B, 4.6% operational sales growth and 3.0% adjusted operational sales growth
 	Enterprise sales highlights can be found on page 5 of the final Q2 2025 earnings transcript attached
 	P&L highlights can be found on page 6 of the final Q2 2025 earnings transcript attached
o 	Innovative Medicine: $15.2B, 3.8% operational sales growth
 	Innovative Medicine sales highlights can be found on page 5-6 of the final Q2 2025 earnings
transcript attached
o 	MedTech: $8.5B, 6.1% operational sales growth
 	MedTech sales highlights can be found on page 6 of the final Q2 2025 earnings transcript attached

-- 4 of 6 --

1 	Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2025
(Unaudited; Dollar in millions)
Earnings before provision for taxes on income by segment
1
Innovative Medicine
Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$1 3,873 	1 00.0 	$1 5,202 	1 00.0 	$1 5,563 	1 00.0 	$1 5,763 	1 00.0 	$60,401 	1 00.0
Cost of products sold (COGS) 	4,020 	29.0 	3,978 	26.2 	3,672 	23.6 	3,976 	25.2 	1 5,646 	25.9
Selling, marketing and administrative expenses (SM&A) 	2,261 	1 6.3 	2,789 	1 8.3 	2,869 	1 8.5 	3,456 	21 .9 	1 1 ,375 	1 8.8
Research and development expense (R&D)* 	2,548 	1 8.4 	2,869 	1 8.9 	2,944 	1 8.9 	3,466 	22.0 	1 1 ,827 	1 9.6
Other segment items 	1 	(1 66) 	(1 .2) 	1 4 	0.1 	(368) 	(2.4) 	(1 93) 	(1 .2) 	(71 3) 	(1 .2)
Adjusted segment income before tax 	2 	$5,21 0 	37.5 	$5,552 	36.5 	$6,446 	41 .4 	$5,058 	32.1 	$22,266 	36.9
Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$1 3,873 	1 00.0 	$1 5,202 	1 00.0 	$1 5,563 	1 00.0 	$1 5,763 	1 00.0 	$60,401 	1 00.0
Cost of products sold (COGS) 	3,371 	24.3 	3,1 80 	20.9 	3,093 	1 9.9 	3,261 	20.7 	1 2,905 	21 .4
Selling, marketing and administrative expenses (SM&A) 	2,261 	1 6.3 	2,789 	1 8.3 	2,869 	1 8.4 	3,456 	21 .9 	1 1 ,375 	1 8.8
Research and development expense (R&D)* 	2,548 	1 8.4 	2,869 	1 8.9 	2,944 	1 8.9 	3,466 	22.0 	1 1 ,827 	1 9.6
Other segment items 	1 	(204) 	(1 .5) 	(1 29) 	(0.8) 	(238) 	(1 .5) 	(1 35) 	(0.9) 	(706) 	(1 .2)
Adjusted segment income before tax 	2 	$5,897 	42.5 	$6,493 	42.7 	$6,895 	44.3 	$5,71 5 	36.3 	$25,000 	41 .4
As reported
Q1 	Q2 	Q3 	Q4 	YTD
Adjusted
Q1 	Q2 	Q3 	Q4 	YTD

-- 5 of 6 --

1 	Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2025
(Unaudited; Dollar in millions)
Earnings before provision for taxes on income by segment
2
MedTech
Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	1 00.0 	$8,541 	1 00.0 	$8,430 	1 00.0 	$8,801 	1 00.0 	$33,792 	1 00.0
Cost of products sold (COGS) 	3,326 	41 .5 	3,638 	42.6 	3,61 2 	42.9 	3,973 	45.1 	1 4,549 	43.1
Selling, marketing and administrative expenses (SM&A) 	2,656 	33.1 	2,862 	33.5 	2,801 	33.2 	3,035 	34.5 	1 1 ,354 	33.6
Research and development expense (R&D)* 	677 	8.4 	647 	7.6 	728 	8.6 	786 	8.9 	2,838 	8.4
Other segment items 	1 	(60) 	(0.7) 	1 90 	2.2 	2 	- 	806 	9.2 	938 	2.8
Adjusted segment income before tax 	2 	$1 ,421 	1 7.7 	$1 ,204 	1 4.1 	$1 ,287 	1 5.3 	$201 	2.3 	$4,1 1 3 	1 2.1
Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	1 00.0 	$8,541 	1 00.0 	$8,430 	1 00.0 	$8,801 	1 00.0 	$33,792 	1 00.0
Cost of products sold (COGS) 	2,795 	34.8 	3,1 42 	36.8 	3,1 1 9 	37.0 	3,435 	39.0 	1 2,491 	37.0
Selling, marketing and administrative expenses (SM&A) 	2,656 	33.1 	2,862 	33.5 	2,801 	33.2 	3,035 	34.5 	1 1 ,354 	33.6
Research and development expense (R&D)* 	671 	8.4 	690 	8.1 	728 	8.6 	786 	8.9 	2,875 	8.5
Other segment items 	1 	(1 82) 	(2.2) 	(53) 	(0.6) 	1 5 	0.2 	1 0 	0.2 	(21 0) 	(0.6)
Adjusted segment income before tax 	2 	$2,080 	25.9 	$1 ,900 	22.2 	$1 ,767 	21 .0 	$1 ,535 	1 7.4 	$7,282 	21 .5
As reported
Q1 	YTD
Adjusted
Q1 	YTD
Q2
Q2
Q3
Q3
Q4
Q4

-- 6 of 6 --